DaVita HealthCare Partners Receives Average Rating of “Buy” from Analysts (NYSE:DVA)
DaVita HealthCare Partners (NYSE:DVA) has been given an average recommendation of “Buy” by the twelve brokerages that are currently covering the company, AnalystRatingsNetwork.com reports. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $75.33.
In other DaVita HealthCare Partners news, VP Leanne M. Zumwalt sold 3,214 shares of the company’s stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $74.57, for a total value of $239,667.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
DVA has been the subject of a number of recent research reports. Analysts at Deutsche Bank downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research note on Friday, August 15th. They now have a $77.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Friday, August 1st. They now have a $74.00 price target on the stock. Finally, analysts at Raymond James downgraded shares of DaVita HealthCare Partners from an “outperform” rating to a “market perform” rating in a research note on Monday, July 21st. They now have a $75.00 price target on the stock.
DaVita HealthCare Partners (NYSE:DVA) traded up 0.47% on Thursday, hitting $74.90. The stock had a trading volume of 30,468 shares. DaVita HealthCare Partners has a 52-week low of $52.75 and a 52-week high of $75.27. The stock’s 50-day moving average is $72.70 and its 200-day moving average is $70.32. The company has a market cap of $16.089 billion and a P/E ratio of 23.60.
DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.95 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.89 by $0.06. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.10 billion. During the same quarter in the prior year, the company posted $1.84 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. On average, analysts predict that DaVita HealthCare Partners will post $3.62 earnings per share for the current fiscal year.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Receive News & Ratings for DaVita HealthCare Partners Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.